AstraZeneca strengthens innovation partnership in India
Leading global science-led biopharmaceutical company AstraZeneca has announced its decision of further investing $ 90 million over the next 5 years in India. The announcement was made following a meeting between the company’s Executive Vice President for International Region – Leon Wang and Prime Minister of India, Narendra Modi, during the latter’s visit to Sweden, where the two countries signed a joint declaration on innovation partnership for a sustainable future.
This investment commitment will span across AstraZeneca’s diverse footprint in India with an aim to strengthen its manufacturing, clinical operations, patient safety & regulatory science, IT services and commercial operations. Furthermore, this investment will support scientific data generation, quality manufacturing, science talent development and collaborative development of innovative solutions to improve the standard of care of non-communicable diseases in India. The commitment also aligns closely with the Indian government’s initiatives to create a stronger business, innovation, and healthcare environment such as “Skill India”, “National Health Policy” and “Ayushman Bharat.”
AstraZeneca’s strategy in India is to address the growing burden of non-communicable diseases. The company invests in many initiatives and programmes such as the Young Health Programme, Early action in Diabetes & Healthy Lung for early action in awareness, prevention, detection and holistic management of non-communicable diseases.